×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ETON – eton pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ETON
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/3
04:30 pm
eton
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
Low
Report
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
3/3
09:51 am
eton
Eton Pharmaceuticals (ETON) had its price target raised by Craig Hallum from $29.00 to $30.00. They now have a "buy" rating on the stock.
Low
Report
Eton Pharmaceuticals (ETON) had its price target raised by Craig Hallum from $29.00 to $30.00. They now have a "buy" rating on the stock.
3/2
08:03 am
eton
Eton Pharmaceuticals (ETON) had its price target raised by HC Wainwright from $35.00 to $37.00. They now have a "buy" rating on the stock.
Medium
Report
Eton Pharmaceuticals (ETON) had its price target raised by HC Wainwright from $35.00 to $37.00. They now have a "buy" rating on the stock.
3/2
08:01 am
eton
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution [Yahoo! Finance]
Medium
Report
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution [Yahoo! Finance]
3/2
07:27 am
eton
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
Medium
Report
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
2/25
02:23 pm
eton
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution [Yahoo! Finance]
Medium
Report
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution [Yahoo! Finance]
2/25
01:47 pm
eton
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution
Low
Report
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution
2/20
07:07 am
eton
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th [Yahoo! Finance]
Medium
Report
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2025
04:05 pm
ETON
eton pharmaceuticals, inc.
MISS
Report
-11.7%
eton pharmaceuticals, inc.
8/7/2025
04:05 pm
ETON
eton pharmaceuticals, inc.
BEAT
Report
12.3%
eton pharmaceuticals, inc.
5/13/2025
04:01 pm
ETON
eton pharmaceuticals, inc.
MISS
Report
0.3%
eton pharmaceuticals, inc.
3/18/2025
06:50 am
ETON
eton pharmaceuticals, inc.
MISS
Report
-4.6%
eton pharmaceuticals, inc.
Date
Time
Symbol
Headline
Impact
3/2
07:00 am
eton
Form 8-K Eton Pharmaceuticals, For: Feb 27
Medium
Report
Form 8-K Eton Pharmaceuticals, For: Feb 27
2/25
02:18 pm
eton
Form 8-K Eton Pharmaceuticals, For: Feb 25
Medium
Report
Form 8-K Eton Pharmaceuticals, For: Feb 25
2/5
05:19 pm
eton
Form 4 Eton Pharmaceuticals, For: Feb 03 Filed by: RIEDEL NORBERT G
Medium
Report
Form 4 Eton Pharmaceuticals, For: Feb 03 Filed by: RIEDEL NORBERT G
2/2
07:00 am
eton
Form 8-K Eton Pharmaceuticals, For: Feb 02
Low
Report
Form 8-K Eton Pharmaceuticals, For: Feb 02
1/14
06:09 pm
eton
Form 4 Eton Pharmaceuticals, For: Jan 12 Filed by: RIEDEL NORBERT G
Low
Report
Form 4 Eton Pharmaceuticals, For: Jan 12 Filed by: RIEDEL NORBERT G
1/14
06:08 pm
eton
Form 4 Eton Pharmaceuticals, For: Jan 12 Filed by: Adams Jennifer McKie
Low
Report
Form 4 Eton Pharmaceuticals, For: Jan 12 Filed by: Adams Jennifer McKie
1/14
06:07 pm
eton
Form 4 Eton Pharmaceuticals, For: Jan 12 Filed by: MAIER PAUL V
Low
Report
Form 4 Eton Pharmaceuticals, For: Jan 12 Filed by: MAIER PAUL V
1/14
06:07 pm
eton
Form 4 Eton Pharmaceuticals, For: Jan 12 Filed by: CASAMENTO CHARLES J
Low
Report
Form 4 Eton Pharmaceuticals, For: Jan 12 Filed by: CASAMENTO CHARLES J
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/27
Eton Pharmaceuticals Announces Acquisition of U.S Marketing Rights to Pediatric Orphan Drug Alkindi® Sprinkle
34.2%
10/22 Eton Pharmaceuticals Announces U.S. FDA Approval of Biorphen® (phenylephrine HCI) Injection 18.4%
4/8 Form D Eton Pharmaceuticals, 11.0%
3/25 Eton Pharmaceuticals Inc (NASDAQ: ETON) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.2%
3/12 Eton Pharmaceuticals Inc (NASDAQ: ETON) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 8.9%
1/28 Eton Pharmaceuticals Inc (NASDAQ: ETON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock, up previously from $21.00. 8.0%
9/20 Eton Pharmaceuticals Inc (NASDAQ: ETON) is now covered by analysts at B. Riley. They set a "buy" rating and a $13.50 price target on the stock. 7.0%
3/16 Form 4 Eton Pharmaceuticals, For: Mar 12 Filed by: BRYNJELSEN SEAN 6.9%
4/6 Form 3 Eton Pharmaceuticals, For: Mar 26 Filed by: Opaleye Management Inc. 5.5%
11/13 Eton Pharmaceuticals Announces $10 Million Debt Facility with SWK Holdings 4.5%
10/22 Eton Pharmaceuticals Announces U.S. FDA Approval of Biorphen® (phenylephrine HCI) Injection 18.4%
4/8 Form D Eton Pharmaceuticals, 11.0%
3/25 Eton Pharmaceuticals Inc (NASDAQ: ETON) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.2%
3/12 Eton Pharmaceuticals Inc (NASDAQ: ETON) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 8.9%
1/28 Eton Pharmaceuticals Inc (NASDAQ: ETON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock, up previously from $21.00. 8.0%
9/20 Eton Pharmaceuticals Inc (NASDAQ: ETON) is now covered by analysts at B. Riley. They set a "buy" rating and a $13.50 price target on the stock. 7.0%
3/16 Form 4 Eton Pharmaceuticals, For: Mar 12 Filed by: BRYNJELSEN SEAN 6.9%
4/6 Form 3 Eton Pharmaceuticals, For: Mar 26 Filed by: Opaleye Management Inc. 5.5%
11/13 Eton Pharmaceuticals Announces $10 Million Debt Facility with SWK Holdings 4.5%
TOP News Decliners
3/31
Eton Pharmaceuticals Inc (NASDAQ: ETON) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.50 price target on the stock.
-16.0%
3/5 Eton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -14.9%
3/17 Eton Pharmaceuticals Reports Positive Study Results for ET-101 (Topiramate Oral Solution) -14.8%
7/12 Eton Pharmaceuticals Provides Update on EM-100 Program -11.1%
3/18 Form 8-K Eton Pharmaceuticals, For: Mar 17 -10.4%
10/22 Form 8-K Eton Pharmaceuticals, For: Oct 22 -8.3%
3/30 Form 8-K Eton Pharmaceuticals, For: Mar 26 -8.3%
2/19 Eton Pharmaceuticals Provides Update on ET-105 Program -7.0%
10/23 Eton Pharmaceuticals Inc (NASDAQ: ETON) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.6%
8/5 Eton Pharmaceuticals Inc (NASDAQ: ETON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock. -5.6%
3/5 Eton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -14.9%
3/17 Eton Pharmaceuticals Reports Positive Study Results for ET-101 (Topiramate Oral Solution) -14.8%
7/12 Eton Pharmaceuticals Provides Update on EM-100 Program -11.1%
3/18 Form 8-K Eton Pharmaceuticals, For: Mar 17 -10.4%
10/22 Form 8-K Eton Pharmaceuticals, For: Oct 22 -8.3%
3/30 Form 8-K Eton Pharmaceuticals, For: Mar 26 -8.3%
2/19 Eton Pharmaceuticals Provides Update on ET-105 Program -7.0%
10/23 Eton Pharmaceuticals Inc (NASDAQ: ETON) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.6%
8/5 Eton Pharmaceuticals Inc (NASDAQ: ETON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock. -5.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: